NDC 47783-646

TAKHZYRO

Lanadelumab-flyo

TAKHZYRO is a Subcutaneous Solution in the Human Prescription Drug category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is Lanadelumab.

• Product ID: 47783-646_b9f42ab3-57b5-4789-a4d9-ac1e11cb120d
• NDC: 47783-646
• Product Type: Human Prescription Drug
• Proprietary Name: TAKHZYRO
• Generic Name: Lanadelumab-flyo
• Dosage Form: Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2022-02-08
• Marketing Category: BLA /
• Application Number: BLA761090
• Labeler Name: Takeda Pharmaceuticals America, Inc.
• Substance Name: LANADELUMAB
• Active Ingredient Strength: 300 mg/2mL
• Pharm Classes: Kallikrein Inhibitors [MoA], Plasma Kallikrein Inhibitor [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 47783-646-01

1 SYRINGE, GLASS in 1 CARTON (47783-646-01) > 2 mL in 1 SYRINGE, GLASS

• Marketing Start Date: 2022-02-08
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "TAKHZYRO" or generic name "Lanadelumab-flyo"

NDC	Brand Name	Generic Name
47783-644	TAKHZYRO	lanadelumab-flyo
47783-646	TAKHZYRO	lanadelumab-flyo